Qlucore receives first commercial order for new solution
Neoscreen Medical Ltd will use Qlucore’s new precision-based leukemia diagnostics.
The Swedish software company Qlucore has signed an agreement with Neoscreen Medical Ltd., Qlucore’s first contract for its new solutions for precisions diagnostics. Neoscreen will use Qlucore’s highly configurable for RNA-seq based diagnostics software to facilitate and speed up decision support and diagnostics for acute lymphoblastic leukemia (ALL).
Cancer diagnostics are changing rapidly and Qlucore is at the forefront of this development. The first application area for Qlucore’s diagnostics platform is RNA-seq based cancer diagnostics in leukemia.
Carl-Johan Ivarsson, CEO at Qlucore, comments: "Our solutions makes it easier and speeds up cancer diagnostics. Detection and analysis of gene fusions and expression-based classification is moving quickly from research to clinical use. We are proud to support Neoscreen and help them provide their clients’ diagnostics support with fast and visual results."
Transcriptional profiling of cancer has a great clinical utility to significantly improve clinical diagnostics. Addition of RNA sequencing in the diagnostics workup of leukemia (ALL) is becoming increasingly important for clinical decision-making as it allows unbiased detection of gene fusions and subtype classification based on gene expression signatures not accessible by DNA-based gene panel analysis. Gene fusions are important diagnostic markers according to the current guidelines for leukemia (ALL and AML).
Yannis L. Loukas, Neoscreen Scientific Director and Assoc. Professor at Athens School of Pharmacy, Greece, comments: “We are delighted to broaden our service with this new RNA-seq based cancer diagnostics platform from Qlucore. This will enable us to provide genetic subtype classifications of leukemia and unbiased gene fusion analysis to our clients.”
Qlucore’s solutions are currently available for research use only and work is ongoing to obtain a CE mark. The company’s advanced software enables faster and better precision-based cancer diagnostics where the AI-powered machine learning based components makes it possible to subtype patients. Qlucore’s software solutions are unique and with combined advanced visualization, mathematics and biology, makes it accessible to the user. Qlucore is well established with leading academic institutions and pharmaceutical companies.
About Neoscreen Medical Ltd.
Neoscreen Medical Ltd. was founded in 2007 as a Laboratory of Neonatal and Prenatal Testing. It started its activities with the expanded control of newborns in order to sort out suspicious cases concerning 60 metabolic diseases. So far we have carried out about 80,000 testings. We then expanded our genetic testing activities to detect germline mutations, having performed more than 70,000 genetic testing (September 2020). Our services range from the detection of a specific mutation to the analysis of the entire genome. Neoscreen is an ISO 15189 accredited laboratory and performs molecular diagnostic testing including molecular onclology tests.
STREAMWIDE selected for phase 3 in the european Broadway project within the consortium led by Airbus
Following the successful completion of Phase 2 last July, Airbus'submitted offer has thoroughly convinced the Technical Validation Committee (TVC) and Lead Procurer for the final Phase of the program. The consortium therefore swiftly makes its way towards the third and final Phase of the i...
STREAMWIDE retenu pour la grande finale du projet européen Broadway, au sein du consortium mené par Airbus
_ Paris, le 20 octobre 2021 – Le consortium, dirigé par Airbus DS SLC et dont STREAMWIDE fait partie, a été sélectionné pour la phase trois du projet d'innovation paneuropéen de haut débit mobile interopérable BroadWay, projet d'a...
Sidetrade : Forte croissance des revenus récurrents SaaS (+16%)
Dans la lignée des deux premiers trimestres de l’exercice 2021, Sidetrade continue d’afficher une dynamique de croissance à deux chiffres pour ce troisième trimestre, période historiquement la plus faible de l’année. Sidetrade réalise un chiffre d’affaires au troisième trimestre 2021 de 8,2 M€, en c...
Sidetrade: Double-digit growth in SaaS recurring revenue, up 16%
Also notable was Sidetrade’s continued international expansion with prestigious groups such as Veolia (Veolia España and Veolia Water Technologies UK), as well as the Page Group with the roll-out of Sidetrade technology in Asia-Pacific. Overall, international SaaS orders represented 58% of the total...